Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.14 USD
+0.02 (1.79%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $1.14 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
SLS 1.14 +0.02(1.79%)
Will SLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SLS
Galena Biopharma (SLS) Upgraded to Buy: Here's What You Should Know
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
SLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Other News for SLS
Solstice Minerals Director Increases Shareholding
Solaris Reports 11,570 g/t Silver and 12.3 g/t Gold in First Assays From Sampling Epithermal Mineralization Discovered As Part of Warintza Regional Exploration Program
Solaris Unveils High-Grade Silver and Gold Assays
Solaris Announces Results of Annual General Meeting of Shareholders
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia